Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trialArlene O. Siefker‐Radtke, Wei Xue, Nobuaki Matsubara et al.|Annals of Oncology|2023Cited by 82
Anti-osteosarcoma effect of hydroxyapatite nanoparticles both <i>in vitro</i> and <i>in vivo</i> by downregulating the FAK/PI3K/Akt signaling pathwayRenxian Wang, Wei Tian, Xiaohui Niu et al.|Biomaterials Science|2020Cited by 39
Psychological changes before and after TVT-O in the treatment of female stress urinary incontinenceXin Li, Jianye Wang, Jianlong Wang et al.|Zhonghua miniao waike zazhi|2013Cited by 0